CRISPR Therapeutics AG CRSP
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 6.59% | 3.56% | -47.42% | -58.80% | -103.80% |
| Total Depreciation and Amortization | -0.87% | -1.44% | -0.52% | 1.14% | -3.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -60.82% | -68.37% | 148.99% | 202.87% | 159.54% |
| Change in Net Operating Assets | -77.18% | 154.75% | 158.76% | -54.00% | 206.60% |
| Cash from Operations | -23.85% | -13.80% | -30.51% | -141.65% | -60.20% |
| Capital Expenditure | -219.97% | -118.97% | 12.55% | 51.92% | 72.70% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,277.33% | -11,389.83% | -109.69% | 88.91% | 108.05% |
| Cash from Investing | -1,303.80% | -9,774.49% | -108.85% | 88.66% | 107.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -58.55% | 986.43% | 1,036.25% | 28.15% | -7.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 120.52% | 2,471.69% | 2,649.46% | 28.33% | -7.78% |
| Foreign Exchange rate Adjustments | -371.43% | -147.71% | -29.03% | 552.38% | -94.49% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -261.09% | 132.39% | 139.09% | 154.00% | 120.11% |